Search

Bosutinib

[L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

Efinaconazole

It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

Asparagine

It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)

Silver sulfadiazine

Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

Abetimus

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Concizumab

Concizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy. … [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway.

Aurothioglucose

Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression...

Mebendazole

A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]

Bimoclomol

Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

2-ethylhexyl benzoate